Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib Combined with Low-Dose Radiotherapy or Rituximab for Ocular Adnexal MALT Lymphoma
NCT07247383Phase 2Active, not recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Sep 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Sep 2025; status: active, not recruiting.
02
Drugs
orelabrutinib
Beyond the preview
Go deeper on NCT07247383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07247383.